The VCAM1–ApoE pathway directs microglial chemotaxis and alleviates Alzheimer’s disease pathology
Lau S, Wu W, Wong H, Ouyang L, Qiao Y, Xu J, Lau J, Wong C, Jiang Y, Holtzman D, Fu A, Ip N. The VCAM1–ApoE pathway directs microglial chemotaxis and alleviates Alzheimer’s disease pathology. Nature Aging 2023, 3: 1219-1236. PMID: 37735240, PMCID: PMC10570140, DOI: 10.1038/s43587-023-00491-1.Peer-Reviewed Original ResearchConceptsDanger-associated molecular patternsAlzheimer's diseaseMicroglial chemotaxisAmeliorate AD pathologyDisease pathologyAlzheimer's disease pathologyAmyloid-betaFunctional screeningPlaque-associatedMicroglial clearanceAD pathologyExtrinsic signalsPhagocytic clearanceExacerbate disease pathologyMolecular patternsIL-33ChemotaxisMicroglial functionAlzheimerVCAM1Interleukin-33Higher cerebrospinal fluid levelsApoPathwayMicrogliaAn IL1RL1 genetic variant lowers soluble ST2 levels and the risk effects of APOE‐ε4 in Alzheimer’s disease
JIANG Y, Zhou X, Wong H, Li O, Ip F, Chau V, Lau S, Wu W, Wong D, Seo H, Fu W, Lai N, Chen Y, Chen Y, Tong E, Mok V, Kwok T, Mok K, Shoai M, Lehallier B, Moran‐Losada P, O’Brien E, Porter T, Laws S, Hardy J, Wyss‐Coray T, Masters C, Fu A, Ip N, Initiative A. An IL1RL1 genetic variant lowers soluble ST2 levels and the risk effects of APOE‐ε4 in Alzheimer’s disease. Alzheimer's & Dementia 2023, 19 DOI: 10.1002/alz.064428.Peer-Reviewed Original ResearchGenome-wide association studiesGenetic regulationAlzheimer's diseaseGenome-wide association study analysisGenetic variantsPathogenesis of Alzheimer's diseaseAD risk genesDisease-causing roleAPOE-e4 carriersAssociation studiesGenetic variationAmyloid-betaRisk genesMicroglial clearanceBrains of patientsBackground genetic factorsAD therapySevere neurodegenerationMicroglial dysfunctionAb accumulationMicroglial functionDecoy receptorGenetic factorsAPOE-e4IL1RL1